Evaxion Biotech
Evaxion shows 75 percent response in phase II study with AI cancer vaccine
Evaxion presents two-year data from phase II study with EVX-01 at ESMO 2025
Evaxion surges on Nasdaq after licensing agreement with MSD
Danish Evaxion Biotech has entered into a license agreement with...
Avtal
Premium
Evaxion converts debt of EUR 3,5 million
News roundup Tuesday, October 29
From Seed to Success 2024
Rights issue takes Express2ion breast cancer vaccine to phase I
Having validated its vaccine platform in Covid-19, Expres2ion...
ExpreS2ion CEO: “Compelling preclinical package gives us confidence”
Based on its proprietary protein expression platform, ExpreS2ion...
Intervju
News roundup Monday, May 13
AlzeCure
News roundup Friday, March 1
The latest from BioStock
Evaxion develops new precision concept for cancer vaccine
Evaxion Biotech has begun the development of a new...
News roundup Tuesday, January 23
The latest from BioStock
The news sweep Friday 22 December
The latest from BioStock